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Mesenchymal stem cells (MSCs) hold a great promise for application in several therapies due to their unique biological
characteristics. In order to harness their full potential in cell-or gene-based therapies it might be advantageous to enhance some
of their features through gene delivery strategies. Accordingly, we are interested in developing an eﬃcient and safe methodology
to genetically engineer human bone marrow MSC (BM MSC), enhancing their therapeutic eﬃcacy in Regenerative Medicine.
The plasmid DNA delivery was optimized using a cationic liposome-based reagent. Transfection eﬃciencies ranged from ∼2% to
∼35%, resulting from using a Lipid/DNA ratio of 1.25 with a transgene expression of 7 days. Importantly, the number of plasmid
copies in diﬀerent cell passages was quantiﬁed for the ﬁrst time and ∼20,000 plasmid copies/cell were obtained independently of
cell passage. As transfected MSC have shown high viabilities (>90%) and recoveries (>52%) while maintaining their multipotency,
this might be an advantageous transfection strategy when the goal is to express a therapeutic gene in a safe and transient way.
1.Introduction
Mesenchymal stem cells (MSCs) transplantation has been
proven to be an eﬃcient method to treat a large spectrum
of diseases. It is noteworthy that both autologous and allo-
geneic MSCs have not induced host immunoreactivity upon
local transplantation or systemic administrations. Therefore,
MSCs are an ideal carrier to deliver genes into the tissues
of interest for gene therapy applications [1]. Genetically
manipulatedMSCcanbeusedindiﬀerenttherapeuticstrate-
gies, either as immunosuppressive agents or as engineered
cells to secrete a variety of diﬀerent proteins in vitro and
in vivo that could potentially treat a variety of serum
protein deﬁciencies and other genetic or acquired diseases,
such as bone, cartilage, and bone marrow (BM) disorders.
In addition, the ability to genetically modify these MSCs
would further contribute to Tissue Engineering settings
enabling theselectiveenhancementof speciﬁcdiﬀerentiation
pathways [2]. As MSCs are not immunologically rejected
and possibly home to damaged tissues, they represent an
opportunity to deliver therapeutic proteins. The advantages
of MSC gene therapy over pharmaceutical agents are the
potential of long-term eﬀects after a single intervention and
the local expression of the desired gene [3]. Gene therapy
can increase survival of engrafted stem cells when transgenes
are inserted into the cell to prevent or reduce apoptosis and
inﬂammatory injury.
Despite the promise of stem cell-based gene therapy
to have an impact on human health, technical challenges
remain to be solved in order to harness the full potential
of stem cells. Presently, the widely used method to transfer
genes to MSC is performed through defective viruses, such
as adenovirus, lentivirus, and retrovirus [4]. When MSCs
are used to compensate or correct a genetic pathology and
must express the therapeutic gene for the duration of a
patient’s life (permanent expression), integrating viruses,
such as lentivirus or retrovirus, are preferred because of
their well-known capacity for long-term expression. On the
contrary, when MSCs are used to treat noninherited diseases
and are only required to express the therapeutic gene for a
short period of time (transient expression), nonintegrating
vectors including adenoviruses and nonviral gene delivery2 Journal of Biomedicine and Biotechnology
systems are preferred [5]. Although these cells can be
more eﬃciently modiﬁed using viral methods, safety issues
including mutagenesis, toxicity, and the immunogenicity of
the virus itself remain considerable concerns. Alternatively,
and despite its less eﬃciency compared to viral methods, the
advantage of using nonviral methods resides on its safety,
demonstrating no immunogenicity, negligible toxicity, and
easier preparation, and having the ability to carry larger
therapeuticgenes[6].Overall,byusingplasmidsitispossible
to modify genes or introduce new ones to make the cell
undergo apoptosis or survive longer, secrete proteins or
switch oﬀ genes, diﬀerentiate or not diﬀerentiate, and even
proliferate [7]. For these reasons, there is an increased inter-
est in the development of a safe and eﬃcient nonviral gene
delivery system that can overtake the limitations associated
to the viral approach. Importantly, for in vitro analysis
and subsequent use for transplantation, the selected system
should not aﬀect MSC proliferation and diﬀerentiation after
transfection.Amongthecurrentnonviralmethods,liposome
carriers and electroporation-based gene transfer techniques
were determined most eﬃcient for transfecting MSC [8].
Electroporation, while eﬀective in transfecting stem cells, is
rather harsh and leads to excessive cell death [5, 9–11].
In a few reports, some lipofection reagents were
described to successfully introduce transgenes and small
interfering RNAs (siRNAs) into MSC, while these cells
have maintained their proliferation capacity and ability
to diﬀerentiate into diﬀerent mesodermal lineages (bone,
cartilage and fat) without loss of transgene expression [12].
The main reason why cationic liposomes have demonstrated
lower transfection eﬃciencies compared to viral vectors is
that these nonviral vectors are not provided with speciﬁc
devices for controlling intracellular gene traﬃcking, turning
its optimization essential [13, 14]. So far, the development of
liposomal vectors has been an empirical process taking into
account the measurement of liposomal transfection by the
percentageofcellsexpressingareporterproteinencodedbya
plasmid determined either by microscopy or ﬂow cytometry.
Nevertheless, although gene expression is the main goal of
transfection, it depends on several factors including plasmid
uptake, intracellular plasmid stability, plasmid access to
nucleus, and ﬁnally transcription and translation eﬃciency.
In this context, more promising enhanced vectors might
be developed considering that all barriers that delivered
DNA must traverse in its journey from the outside to
the nucleus of target cells. Furthermore, the mechanism
of nuclear transport of the delivered gene, as well as the
relationship between the amounts of gene delivered to the
nucleusandgeneexpression,isunclearatthepresent.Thus,a
quantitative understanding of the intracellular traﬃcking of
plasmids delivered by these vectors is required to understand
the factors governing the eﬃciency of gene expression [14].
To achieve this goal, the quantiﬁcation of the number
of plasmid molecules that enter the cells can not only
contribute to understanding the underlying mechanisms of
liposomal gene delivery but it can also be a helpful tool to
optimize the liposomal vectors increasing their transfection
eﬃciencies. Herein, by using this approach we were able to
determine the optimal amount of delivered DNA required
for the best transgene expression and compare delivery
eﬃciency in diﬀe r e n tc e l lp a s s a g e so fh u m a na d u l tB M -
derived MSC. Overall, we believe our ﬁndings are extremely
useful towards the maximization of gene delivery to human
MSC, without compromising cell function and viability,
when the ﬁnal goal is (i) to express a therapeutic gene
in vivo in a safe and transient way (ii) or to improve
their in vitro expansion or controlled diﬀerentiation by
overexpressionofstemness-orspeciﬁclineagecommitment-
related genes/proteins, respectively.
2.MaterialsandMethods
2.1. Plasmid Construction, Production, and Puriﬁcation.
pVAX-GFP (3697bp) plasmid was obtained by modiﬁcation
ofthecommercialplasmidpVAX1lacZ(6050bp,Invitrogen),
by replacement of the β-galactosidase reporter gene by the
enhanced Green Fluorescent Protein (eGFP, referred to as
GFP thereafter) gene. The details of the construction are
described elsewhere [15].
The plasmid contains the human cytomegalovirus
(CMV) immediate-early promoter, a ColE1 type origin of
replication and the kanamycin resistance gene for bacterial
selection. Plasmid DNA (pDNA) was obtained by growing
E.coli cultures (harbouring pVAX-GFP) overnight, in 2L
shake-ﬂasks containing 250mLLB medium and antibiotics
(30μg/mL of kanamycin). Plasmid puriﬁcation was per-
formed according to the Endotoxin-free Plasmid DNA
Puriﬁcation Kit protocol (Macherey-Nager). The concentra-
tion of puriﬁed pDNA solutions was assayed by spectropho-
tometryat260nm(Nanodrop,ThermoScientiﬁc),andDNA
integrity was conﬁrmed by DNA agarose gels stained with
ethidium bromide.
2.2. Real-Time PCR for Determination of MSC Plasmid
Content. Quantitative Real-Time PCR was performed by
ampliﬁcation of a 108bp sequence within the GFP gene
(forward primer: 5 -TCG AGC TGG ACG GCG ACG TAA
A-3 ;reverseprimer:5 -TGCCGGTGGTGCAGATGAAC-
3 ). PCR reactions were carried out in a Roche LightCycler
detection system using the FastStart DNA Master SYBR
Green I kit (Roche Diagnostics) as recommended by the
manufacturer. Each 20μL of ﬁnal reaction volume contained
2.0μL of the 10x SYBR Green mixture, 0.4μLo fe a c hp r i m e r
(0.4μM ﬁnal concentration), 1.6μLo fM g C l 2 solution
(3.0mM ﬁnal concentration), and 2–7μL of our sample
(corresponding volume to 10,000MSC) and the remaining
volume was fulﬁlled by PCR grade water. Reactions were
incubated at 95
◦C for 10 minutes to activate FastStart DNA
polymerase and lyse cells, followed by 40 cycles of 10 seconds
at 95
◦C, 5 seconds at 55
◦C, and 7 seconds at 72
◦C( a d a p t e d
from [16]).
Calibration curves were constructed by adding serial
dilutionsofpDNAstandards(pVAX-GFP)toasuspensionof
nontransfected MSC cells (10,000 cells per reaction). These
samples were then mixed with the other PCR reagents as
describedabove.Twonegativecontrolswerealwaysincluded;
one containing the same amount of nontransfected cells,Journal of Biomedicine and Biotechnology 3
exposed to the pDNA, but not to Lipofectamine, and in the
other, PCR grade water was used instead of control cells to
detect undesired contamination.
2.3. Mesenchymal Stem Cells Isolation, Thawing, and Expan-
sion. Bone marrow (BM) aspirates were obtained from
adult volunteer donors, after informed consent at Instituto
Portuguˆ es de Oncologia de Lisboa Francisco Gentil. Low
density BM mononuclear cells (MNCs) were separated
by a Ficoll density gradient (1.077g/ml) (GE Healthcare)
and then washed twice in Dulbecco’s Modiﬁed Essential
Medium (DMEM, Gibco) with 10% Fetal Bovine Serum
(FBS) MSC qualiﬁed (GibcoBRL), 1% (v/v) penicillin
(10,000U/mL)/streptomycin (10,000g/ml), and 0.1% (v/v)
Fungizone (Gibco). BM MNCs were then plated at a density
of 2 × 105 cells/cm2 on plastic culture ﬂasks in DMEM
with 10% FBS at 37
◦C and 5% CO2 in a humidiﬁed
atmosphere. Medium was changed twice a week. BM MSCs
were isolated based on adherence to plastic, and near cell
conﬂuence (70%–80%) exhausted medium was removed
from the ﬂasks, cells were washed with phosphate buﬀered
saline (PBS; Gibco) and detached from the ﬂask by adding
Accutase solution (Sigma) for 7 minutes at 37
◦C. Upon
isolation, MSCs were expanded for 2–4 passages and kept
frozen in liquid nitrogen. Isolated BM MSC, expressed their
characteristic immunophenotype being CD73, CD90, and
CD105 positive and negative for CD31, CD34, CD45, and
CD80 [17]. When necessary, cells were thawed in a 37
◦C
water bath during approximately 1 minute and resuspended
in 5mL of prewarmed Iscove’s modiﬁed Dulbecco’s medium
(IMDM, Gibco) supplemented with 20% FBS. Then the
suspension was centrifuged at 1250rpm for 7 minutes, and
the pellet was resuspended in prewarmed (37
◦C) DMEM-
10% FBS. After determination of the cell number and cell
viability using the Trypan Blue (Gibco) dye exclusion test,
the cells were plated on 75cm2 T-ﬂasks at a density of 3000–
6000 cells/cm2 a n dk e p ta t3 7
◦C in a humidiﬁed atmosphere
containing 5% CO2. The medium was changed every 3-
4 days. When cultures reached approximately 80%–90%
conﬂuence, cells were washed with PBS and harvested by
enzymatic treatment (Accutase; Sigma). After discarding the
supernatant, the cells were resuspended in 1mL DMEM.
Finally, cells were counted and seeded on T-ﬂasks or 24 well-
plates for the transfection protocol.
2.4. Lipofection. A total number of 50,000 cells were
plated per well in a 24-well plate. After 24 hours,
Lipofectamine2000-mediated (LF2000) (1mg/mL) (Invit-
rogen) transient transfection was performed according to
the protocol given by the supplier (Invitrogen), varying
transfection reagent volumes and the amount of DNA
(pVAX-GFP)inratiosLF2000/pDNAfrom1to2.5.Dilutions
of pVAX-GFP and LF2000 were carried out in OPTIMEM
1 (Gibco), without serum or antibiotics. Before the trans-
fection, mixture has been added to the adherent MSC, and
the culture medium was changed to serum- and antibiotics-
free DMEM. Five hours after transfection the medium was
replacedwithfresh500μLDMEMsupplementedwithserum
and antibiotics. Cell viability was determined by trypan
blue exclusion method. For each transfected sample (t), Cell
Recovery (CR) was determined using the equation
CR(%)t =
CAt
CAc
×100, (1)
where CAtis the number of transfected cells alive, and CAc is
the number of non-transfected cells alive (control).
2.5. Detection of GFP Expression and Cell Sample Preparation
for RT-PCR. Determination of transfection eﬃciency was
performed 24 hours after transfection through ﬂuorescence
microscopy and ﬂow cytometry analysis. Culture medium
was removed and 500μL of PBS were added to each well.
Cellswereobservedimmediatelyunderaﬂuorescenceoptical
microscope Leica DMI 3000B (Leica Microsystems GMbH),
and digital images were taken with a digital camera Nikon
DXM 1200F.
Cells were then harvested by enzymatic treatment, and
cells suspension was then collected into a conical tube
and centrifuged at 1250rpm for 7 minutes, and after
discarding the supernatant, the cells were resuspended in
1mL PBS. Thereafter, 500μL of this cell resuspension were
collected into FACS tubes for GFP expression analysis using
a FACScalibur equipment and the CellQuest software (BD
Biosciences). The other 500μL were used to determine the
cellnumberandcellviabilityaspreviouslydescribed.Finally,
cells were centrifuged again at 2500rpm for 6 minutes, the
supernatant solution was removed, and pellets were stored at
−80
◦C for subsequent Real-Time PCR analysis.
2.6. Immunophenotyping and Evaluation of Multilineage
Diﬀerentiative Potential. Approximately 50,000 transfected
and non-transfected (control) MSCs per FACS tube were
incubated in the dark, with phycoerythrin- (PE-) conjugated
monoclonal antibodies anti-CD73PE (BD Biosciences),
CD105PE (Invitrogen), and CD90PE (RD Systems), for 15
minutes at room temperature. Then the cells were washed
in PBS and ﬁxed with 2% (w/v) paraformaldehyde (PFA;
Sigma). Appropriate isotype controls IgG γ1a n dI g Gγ2( B D
Biosciences) were also considered.
WhenculturedMSCreachedtotalconﬂuence,osteogenic
and adipogenic diﬀerentiation was induced through replace-
ment of expansion medium by Stem PRO(R) Osteogenesis
Diﬀerentiation kit and Stem PRO (R) Adipogenesis Diﬀer-
entiation kit (Gibco), respectively. The medium was changed
every 4 days and after 14 days on culture the diﬀerentiative
potential ofMSCwascheckedbyobservationofthestandard
staining tests.
Oil red-O staining (adipogenesis). Cells in culture were
washed with PBS, ﬁxed with 2% (w/v) PFA for 45 minutes,
washed again with distilled water and incubated with 0.3%
Oil Red-O solution (Sigma) for 1 hour. After a second
wash with distilled water, cells were observed under the
microscope.4 Journal of Biomedicine and Biotechnology
Alkaline Phosphatase and Von Kossa Stainings (osteogenesis).
C e l l si nc u l t u r ew e r ew a s h e dw i t hP B S ,ﬁ x e dw i t h2 %
PFA for 45 minutes, and washed again with distilled water.
Then cells were incubated in a solution of 1:3 Naphtol
AS-MX phosphate and Fast Violet (Sigma) for 45 minutes,
washed three times with distilled water, and observed under
the microscope. Cells were then stained for Von Kossa by
incubation with 2.5% (w/v) Silver Nitrate solution (Fluka)
for 30 minutes and were ﬁnally observed.
2.7. Colony-Forming Units (CFUs) Assay. MSC were plated
on 25cm2 T-ﬂasks with 5mL DMEM containing 10% FBS
(MSC qualiﬁed) at a density of 10 cells/cm2 (250 cells
per T-ﬂask). After 14 days in culture, without medium
replacement, the cells were washed with PBS, a solution
of 0.5% (w/v) crystal violet (Sigma) was added and the
cells were kept at room temperature for 30 minutes. After
crystal violet solution removal, the cells were washed 4 times
with PBS and 1 time with distilled water. Finally, all the
freestanding water was pipetted oﬀ and when the T-ﬂasks
were dry, the number of colony-forming units (CFUs) was
counted.
3. Results
3.1.LipofectionOptimization. Diﬀerentstrategiesweretested
to enhance and optimize the MSC transfection protocol
using Lipofectamine2000 (LF2000). The evaluation of the
transfection eﬃciency was based on the percentage of cells
expressing GFP assessed by cytometry analysis and on the
determination of plasmid copy number by quantitative real-
time PCR. To obtain the highest transfection eﬃciency and
low cytotoxicity, transfection conditions were optimized by
varying pDNA (D) and LF2000 (L) amount. Lipoplexes
were ﬁrstly prepared using three diﬀerent L/D ratios using
the same amount of pDNA (2μg). Although it could be
observed nearly the same number of GFP positive (GFP+)
cells in all three L/D ratios (approximately 10%), the average
number of plasmids per cell for L/D = 2 is 2.5-fold higher
when compared to the other studied L/D ratios (Figure 1).
By phase contrast microscopic images of transfected MSC
(Figure2(a))itwaspossibletoverifythatnorelevantchanges
have occurred in MSC morphology upon lipoplexes contact.
Moreover,cellsexpressingGFP(Figure2(b))alsomaintained
the characteristic spindle-shaped morphology of MSC. By
ﬂow cytometry we compared the number of GFP+ cells of
transfectedsampleswithacontrol(cellspreviouslyincontact
with the same amount of lipid). In Figure 2(c) an overlay
of two histograms of transfected and non-transfected cells
is shown. Around 35% of the cells were GFP+ with mean
ﬂuorescence intensity (MFI) around 1000a.u. (% Gated and
Mean of M2, respectively, shown on the table).
Transgene expression on MSC was evaluated up to 7 days
after transfection (Figures 3(a) and 3(c)). This assay was
performed using lipoplexes with L/D ratios 1.25, 2, and 2.5.
Varyingeitherlipidamount(2.5μLor4μL)orDNAquantity
(1μgo r2 μg) a 70% decrease of GFP+ cells was observed
along 7 days (Figures 3(a) and 3(c)). Cellular viabilities and
0
5
10
15
20
P
l
a
s
m
i
d
c
o
p
y
n
u
m
b
e
r
/
c
e
l
l
G
F
P
p
o
s
i
t
i
v
e
c
e
l
l
s
(
%
)
L/D 1 L/D 1.25 L/D 2
Lipid/DNA ratio
pDNA copy number/cell
GFP + cells (%)
1.4E+05
1.2E+05
1E+05
8E+04
6E+04
4E+04
2E+04
0E+00
Figure 1: Diﬀerences between the percentage of GFP positive cells
assessed by ﬂow cytometry analysis (white bars) and intracellular
plasmid copy number determined by RT-PCR (grey  ). MSCs
were transfected with three diﬀerent Lipofectamine/pDNA (L/D)
ratios: 1, 1.25, and 2. Results are the mean of four independent
experiments with standard deviation.
cell recoveries of all studied conditions are shown in Figures
3(b) and 3(d). While higher lipid amounts decreased cell
viability (from 90% to 80%) and cell recovery (from 95%
to 85%), apparently DNA amount did not inﬂuence cell
survival, when using 2.5μL of LF2000.
3.2. Inﬂuence of Cell Passage Number on Transfection Eﬃ-
ciency. Typically, as MSCs are rare in their niches (as the
BM), they have to be cultivated for several passages in
order to reach clinically relevant cell numbers. Thus, the
inﬂuence of MSC passage number on transfection eﬃciency
was studied herein. To this end, MSCs from 2 diﬀerent
donors, from passage 1 to 4, were used. The cells were
analysed by evaluating the number of cells expressing GFP,
the MFI value (measure of GFP expression level), and the
number of plasmids per cell (Figures 4(a), 4(b) and 4(c),
resp.). We have found that the percentage of GFP+ cells and
the MFI decreased with the passage number for both donors.
This decrease is more evident between passages 1 and 2.
At early passages, the number of GFP+ cells or the MFI
was donor dependent since the percentage of GFP+ cells is
4-fold higher for one of the donors. Interestingly, the average
number of plasmids per cell appeared to be approximately
constant (∼20,000plasmids/cell) and independent of the
donor and passage number (Figure 4(c)). This seems to
indicate that the decrease in the number of GFP+ cells
observed at higher passages is not related to plasmid uptake
by the cell but to the eﬃciency of GFP expression. This
higher eﬃciency observed at lower passages may be the
result of a higher nuclear uptake and/or a more eﬃcient
transcription/translation of the GFP gene.Journal of Biomedicine and Biotechnology 5
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Figure 2: Bright ﬁeld (a) and ﬂuorescence (b) microscopic images of lipofectamine-mediated pDNA-GFP transfer in MSC, 24 hours after
transfection. Images obtained by ﬂuorescence optical microscopy (100x). Flow cytometry proﬁles of nontransfected hMSC (white) and
hMSC transfected with pDNA-GFP using Lipofectamine2000 L/D = 1.25 (grey) and respective statistical analysis (c).
Cell viability and cell recovery after transfection are
criticalparameterstoconsiderwhendeterminingtheeﬃcacy
of nonviral gene delivery methodology. By analysing Table 1,
it is remarkable that, under optimal transfection conditions
(L/D = 1.25 and plating cell density of 25,000 cells/cm2),
LF2000 led to high cell viabilities at all cell passages (90%–
95%). Moreover, cell recoveries from 50% to 98% were
obtained, which is the real measure of the number of cells
that remained adherent, and supposedly functional, after
lipoplexes uptake.
3.3. Assessment of Lipofected MSC Multipotency. According
to the high capacity of MSC to proliferate and diﬀerentiate
in vitro into diﬀerent mesodermal lineages, both clonogenic
and diﬀerentiative potential assays were performed to verify
to what extent lipofection could aﬀect MSC characteristics.
It was also analysed if MSC maintained their characteristic
immunophenotypic proﬁle. In order to verify if MSC
maintained the capacity to proliferate and originate colonies,
a CFU assay was carried out for transfected MSC and two
controls. One control included cells incubated with 2.5μL
of LF2000 (Figure 5(a), white bar) and the other cells that
were neither in contact with LF2000 nor pDNA (Figure 5(a),
grey bar). The transfected cells (black bar), which had a
transfection eﬃciency of nearly 20%, have considerably lost
their clonogenic potential when compared to the control of
cells only (an 85% decrease). Nevertheless, independently6 Journal of Biomedicine and Biotechnology
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Figure 3: Evaluation of GFP expression along 7 days after transfection of MSC with Lipoplexes (a, c) and percentage of cell viability and cell
Recovery of the diﬀerent liposomal formulations measured 24 hours after transfection (b, d). Variation of liposome amount, maintaining
DNA amount (2μg) at charge ratios L/D 1.25 and 2, using 2.5μL and 4μL of LF2000, respectively (a, b). Variation of DNA amount,
maintaining liposome volume (2.5μL) at charge ratios L/D 1.25 and 2.5, using 2μg and 1μg of DNA, respectively (c, d). The data was
obtained from the average of two independent experiments with duplicates ±SEM.
of pDNA transfection, LF2000 itself had a harmful eﬀect
on MSC clonogenic potential, since a decrease of 43%
in colonies was observed. Considering the maintenance of
MSC multilineage diﬀerentiative potential, transfected cells
(with transfection eﬃciency near 20%) were induced to
diﬀerentiate into the adipogenic and osteogenic lineages
(Figure 5). Controls with non-transfected cells and cells
incubated with LF2000 were also performed. As can be
seen in Figures 5(b) and 5(c) transfected MSC were showed
to preserve the capacity to diﬀerentiate into adipocytesJournal of Biomedicine and Biotechnology 7
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Figure 4: Percentage of GFP positive cells (a) and mean ﬂuorescence intensity (b) assessed by ﬂow cytometry analysis and intracellular
plasmid copy number (c) determined by RT-PCR after lipofection of MSC (L/D = 1.25) of two diﬀerent donors, at diﬀerent cell passages.
Results from one experiment with duplicates ±standard deviation are displayed.
Table 1: Percentage of MSC viability and recovery at diﬀerent
passages (1–7), 24 hours after transfection. Controls are non-
transfectedcells.Results are presented as mean±standard deviation
of duplicates.
Passage number
Cell Viability (%) Cell Recovery (%)
Control Transfected cells Transfected cells
1 90.1 (±3.3) 93.6 (±3.8) 52.5 (±11.2)
2 91.5 (±3.1) 89.7 (±8.0) 80.4 (±33.6)
4 85.5 (±4.1) 89.7 (±1.7) 98.0 (±11.5)
5 86.6 (±6.1) 92.4 (±0.6) 79.1 (±6.3)
6 94.1 (±2.9) 94.7 (±1.9) 74.2 (±5.5)
7 91.4 (±0.4) 91.1 (±9.2) 88.0 (±4.6)
(Figure 5(b)) and osteocytes (Figure 5(c)). After 15 days
in culture, the adipogenic diﬀerentiation was conﬁrmed
through the Oil red-O test, where stained red lipid droplets
inside vacuoles of mature adipocytes were visualized. On
the other hand, osteogenic diﬀerentiation was conﬁrmed
with the appearance of nodules that stained positive (in
brown) for calciﬁed matrix through the Von Kossa staining
and an increasing alkaline phosphatase activity was also
observed, which is a distinctive characteristic of osteogenic
commitment (in pink).
Through immunophenotype staining, it was veriﬁed
whether transfected MSC (with a transfection eﬃciency
of nearly 20%) maintained its characteristic phenotypic
proﬁle, namely over 90% positive for CD73, CD90, and
CD105 [18]. As expected, more than 90% of the non-
transfectedcells(control)expressedthethreemarkers.When
analysingthecellpopulationthatunderwentthetransfection
protocol, a slight decrease (<9%) on the percentage of cells
expressing these markers compared to controls was observed
(Table 2). However, when considering only GFP+ cells from
the transfected population, a higher decrease was observed,
namely, 83.0%, 74.2%, and 86.5% of cells expressed CD73,
CD105, and CD90, respectively.
4. Discussion
BM MSCs have been widely investigated due to their
regenerative potential; however, in many cases it might
be useful to enhance some of their features through gene
delivery strategies to harness their full potential in cell/gene-
based therapies.8 Journal of Biomedicine and Biotechnology
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Figure 5: (a) CFU assay of MSC after transfection (in black). Two diﬀerent controls were assayed: cells which have not been in contact with
lipofectamine and pDNA (white), and cells which have only been in contact with lipofectamine (L = 2.5μL—grey). MSC were transfected at
passage 4 with a transfection eﬃciency of ∼20%. Results are presented as mean±SEM of two independent experiments with duplicates. (b)
Oil red-O staining and (c) Alkaline Phosphatase and Von Kossa stainings were tested in order to analyse the maintenance of adipogenic and
osteogenic diﬀerentiation potential after transfection, respectively. The assay was performed in duplicate, and images were obtained through
ﬂuorescence optical microscopy (200x).
Previously, a method for plasmid delivery quantiﬁcation
was successfully established by us, fulﬁlling a lack in the
study of MSC transfection, since an eﬃcient quantiﬁcation
of the number of plasmids that enter into the cell was
required. This new RT-PCR quantiﬁcation method has been
revealed to be an extremely useful tool for the optimization
of MSC transfection using cationic liposomes, particularly
to understand the relationship between expression and the
plasmid uptake within a population of transfected cells.
Recently, an RT-PCR methodology was established to
quantify the number of plasmids inside CHO cells and
bacteria [16]. Taking advantage of the usefulness of this
techniquewehavepreviouslyestablishedarapidquantitative
RT-PCR assay to determine intracellular plasmid DNA in
MSC (submitted for publication). In this previous work,
the RT-PCR method showed good reproducibility, high
sensitivity, and a wide linear range of 75 to 2.5×106 plasmid
DNA copies per cell. The inﬂuence of cell number on the
RT-PCR sensitivity was also evaluated. In the work described
herein we have studied the eﬀect of the initial plasmid
amount, cationic lipid, and cells passage number on the
plasmid uptake for bone marrow-derived MSC.
By varying cationic liposome amount, using the same
quantity of pDNA, we have veriﬁed that major amounts
of lipids did not correlate with higher amounts of pDNA
inside the cells. In fact, it has been shown that for each
cell type there is an optimal dose of plasmid, above which
any additional plasmid will not contribute to transgene
expression even though it may be delivered to the nucleus
[13]. Moreover, higher amounts of transfection reagent were
thought to increase pDNA protection against intracellular
degradation by endonucleases, therefore increasing pDNA
entrance into the nucleus. However, it was reported that
the highest values of DNA protection do not correlate with
highervaluesoftransfectionactivity,evenwhenusingDOPE
[19]. This neutral lipid at physiological pH is included
in LF2000 formulation and reacts to the acidic pH of
endosomespromotingpDNAreleasebeforetheirmaturation
into lysosomes [20]. It was veriﬁed by others that DNA
complexes giving rise to eﬀective transfection are releasedJournal of Biomedicine and Biotechnology 9
Table 2: Immunophenotype evaluation of transfected MSC
through ﬂow cytometry analysis. The identiﬁcation of MSC
characteristic phenotype was assessed by ﬂuorescent-conjugated
monoclonal antibodies against CD73, CD105, and CD90 receptors.
Controls with non-transfected cells were also performed as well as
the appropriate isotype controls IgG γ1 and IgG γ2.
Phenotype marker CD73+ CD105+ CD90+
MSC (control) 96.5% 95.3% 92.1%
Transfected MSC 89.3% 87.0% 89.8%
GFP
+ MSC 83.0% 74.2% 86.5%
from endocytic vesicles at an early stage of endocytosis, that
is, mainly before 1.5 hour after uptake, when the DNA is still
mostly nondegraded [21, 22].
Moreover,recently,theexistenceofanuclearclumpingof
extranuclear DNA was observed 24 hours after transfection
of B16F10 mouse melanoma cells and A549 human lung
carcinoma, with LF2000 [13]. Contrarily, other authors did
not detect extranuclear DNA 24 hours after lipofection of
NIH3T3 cells [23]. Our methodology does not include any
separationstepbeforeRT-PCR.Thisisadvantageousbecause
it is less time consuming but does not allow a distinction
betweenpDNAinsidethenucleusorintheperinuclearspace.
Assuming that diﬀerent cells may lead to diﬀerent rates of
DNA nuclear uptake and knowing that NIH3T3 cells (mouse
embryonicﬁbroblastscellline)mayshowmorephysiological
similarities with BM MSC, which are ﬁbroblast precursors,
we may suggest that plasmid copies detected by our method
24 hours after transfection were mainly from the nucleus.
Nevertheless, higher amount of pDNA copies was obtained
at higher charge ratios (L/D = 2) although not correlating
with higher transgene expression. This lower expression
could be either related to a higher level of DNA aggregation,
within lipids or proteins, in the perinuclear space, or due to
saturation of GFP expression [13, 23], or both. Indeed, with
the increase of cationic reagent, apart from the occurrence
of aggregation, higher number of plasmids may also enter
into the nucleus because, in this case, more pDNA molecules
may be complexed. However, as observed in our case, an
increase in pDNA inside the nucleus could not lead to any
increase in protein expression [13]. Furthermore, we veriﬁed
that this formulation, L/D = 2, led to higher levels of cell
death because a reduction of around 10% in cell viability
and recovery was observed when the lipid amount was
increased from 2.5μLt o4μL. This event may be a reﬂection
of excessive foreign DNA molecules inside these cells. More
fundamental studies on pDNA intracellular traﬃcking in
BM MSC after lipofection are required in order to validate
its kinetics, especially using diﬀerent amounts of DNA and
cationic liposomes.
Since the plasmid used in this study does not have
the capability of replicating inside cell, it will be diluted
after transfection and with consecutive cellular divisions.
Thus it would be expected to observe a decrease in the
number of cells expressing GFP over time as a consequence
of the decrease in plasmid copy numbers inside the cells.
As previously shown by others using CHO cells transfected
with the same plasmid and using an RT-PCR quantiﬁca-
tion method, the plasmid copy number inside these cells
decreases exponentially along seven days [16]. In contrast
to the viral delivery systems, which are frequently used to
long-term expression of a gene of interest, in many cases
of non-inherited diseases it may be desirable to express the
therapeutic gene transiently. In fact, since the transfection
method used was only expressed for a short period of
time (≈7 days) it is an ideal candidate for this kind of
therapeutic approach, such as, MSC transient expression of
anti-inﬂammatory genes to suppress an acute inﬂammation
or expression of homing chemokines to move MSC towards
the site of injury [24]. In addition, the expression proﬁles
reported can also be useful in other Regenerative Medicine
applications, including Tissue Engineering, where prolifer-
ation and/or diﬀerentiation into a speciﬁc lineage can be
favoured by transient expression of a target gene involved in
self-renewal or cell commitment, respectively [25].
Regarding transfection eﬃciencies using cationic lipo-
somes, although the values obtained are still considerably
lower than those obtained with the viral vectors and some
nonviral vectors, namely, electroporation and nucleofection
[25, 26], the results presented herein are very encouraging
since a maximum value of 35% was reached using L/D =
1.25. In fact, from all the available commercial reagents
LF2000 has been shown to be more eﬃcient on MSC
transfection, and eﬃciencies of 5%–20% have been reported
when similar detection methods were used [24, 27].
It is worth mentioning that for some applications lower
transfection eﬃciencies may be required, because in most
cases, high transfection eﬃciencies are directly associated
to a higher cell death [28]. In fact, it was recently shown
that cationic liposomes overcome not only the known
clinical safety problems related to viral vectors but also the
toxicity problem, since lipofectamine toxicity is generally less
than 20%, which is considered to be adequate for several
applications [24, 29].
In this work it was veriﬁed that human MSC transgene
expression is cell passage dependent, in accordance with the
results reported by others using similar [27] and diﬀerent
transfection systems and cells [28, 29]. Indeed, only one
report was found in the literature focusing on the eﬀect of
thecellpassagenumberofMSConthetransfectioneﬃciency
[27]. These authors, however, only studied two diﬀerent
passages (5 and 7). Herein, regardless the decrease in GFP+
cells along cell passages, the same amount of plasmid entered
the cells along the passages. According to our results around
20,000 pDNA copies were detected inside human MSC in
the ﬁrst four passages. The eﬀects of MSC consecutive cell
doublings on their genotypic and phenotypic characteristics
were previously reported [30, 31], but to our best knowledge
noadverseeﬀecthasbeendetectedatpassages2,3,and4.We
hypothesize that upon the ﬁrst passages the transcriptional
mechanism of MSC is being delayed which may explain
the decrease of GFP+ cells and MFI whereas cells enclose
similar amounts of plasmid DNA. Indeed, expression of
nonnative proteins requires extra energy from the cells [32],
and probably at early passages mammalian cells have more
energy available to use in transcriptional activities of foreign10 Journal of Biomedicine and Biotechnology
genes. It is important to notice that our results were obtained
w i t hc e l l sf r o md o n o r sa b o v e6 0y e a r so l d ,a n dc e l l sf r o m
younger donors may lead to diﬀerent results, since in few
studies it has been reported that donors’ age might inﬂuence
for example the replicative lifespan of cells [33] or their
capability to diﬀerentiation [34] which are directly related to
endogenous protein expression along diﬀerent cell passages.
The variability observed for the diﬀerent donors might be
due to intrinsic donor-to-donor variability. To date, and to
our best knowledge, there are no reports establishing any
relationship between plasmid copy number inside cells after
lipofection and passage number of human MSC.
In this work, cell viabilities above 85% surpass those
recently reported by others using nucleofection method for
gene delivery to human MSC. Using this nucleofection pro-
cedure, higher transfection eﬃciency was achieved (∼50%)
but over 50% cell death postnucleofection was induced [26].
Similarly, other authors reported less than 50% cell viability
after MSC electroporation; in this case, a 90% gene delivery
eﬃciency to MSC is reported using 60μgp D N At o1× 106
cells, which in turn represents ∼17,000 cells/μgD N A ,a
lower cell/DNA ratio than the one used in this work (25,000
cells/μgD N A )[ 25]. The cell recovery results obtained by
lipofection (53%–100%) were better than those obtained
by nucleofection (≈40%) [35] or other electroporation
methods (35%–40%) [25]. Interestingly, no other reports on
cell recovery (i.e., the real measure of cells that survived after
lipofection) of MSC lipofection were found in the literature.
In what concerns the multipotency of MSC, it was
possible to conclude that transfection does not aﬀect MSC
diﬀerentiative potential since transfected MSC could diﬀer-
entiate into cells from two diﬀerent mesodermal lineages:
adipocytes and osteocytes. This is especially interesting when
considering MSC as one of the preferable starting cell source
for Tissue Engineering applications.
On the other hand, it is believed that the decrease
observed in the expression of the characteristic markers
CD73, CD90, and CD105, as well as in the clonogenic
potential, does not jeopardize MSC therapeutic potential
especially if one considers that most applications with MSC
in Cellular Therapy are based on their intrinsic trophic
(secretory) activity which is believed to be immunomod-
ulatory (i.e., treatment of graft-versus-host disease). Other
potential applications of MSC would also take advantage
from demonstrated features as being angiogenic, anti-
inﬂammatory,antiapoptotic,andpromitotic[1].Inthiscon-
text, it would be interesting to determine how transfection
can aﬀe c tM S Cs e c r e t o r ya c t i v i t yo fd i ﬀerent factors as for
instance interleukin-10 (IL-10) or vascular endothelial factor
(VEGF).
Although all transfection experiments performed herein
were based on expressing a reporter protein encoded by
a plasmid, our ﬁnal goal is to develop eﬃcient and
safe methodologies to geneticallyengineer MSC to enhance
their therapeutic eﬃcacy in diﬀerent Regenerative Medicine
applications, namely, for tissue regeneration and cancer
treatment. Indeed, genetic modiﬁcation of MSC with genes
encoding for tissue-speciﬁc growth factors and cytokines
(e.g., bone morphogenetic proteins) can promote, both in
vitroandinvivo,lineage-speciﬁcdiﬀerentiationandimprove
tissue function [36]. On the other hand, several studies have
shown that MSCs engineered to express antitumour factors
(e.g., tumour necrosis factor apoptosis ligand (TRIAL),
interferon (IFN)-β,- γ, and interleukin-2) (reviewed in [37])
representanattractivetoolasacell-mediatedgenetherapyto
counteract tumour growth.
5. Conclusions
In summary, this study showed that cationic liposomes are
promising transfection agents to human MSC, especially
for applications only requiring low and transient expression
of proteins. We were able to achieve up to 35% of cells
expressing GFP using L/D = 1.25 at early passages.
Moreover, their diﬀerentiative potential and viability were
not compromised. Furthermore, we found that human MSC
lipofected at diﬀerent passages, using the same amount
of plasmid displayed, diﬀerent levels of protein expression
regardless similar amount of plasmids were detected inside
the cells. These ﬁndings contributed to better understanding
of MSC lipofection and also underlined the need to focus
on more fundamental studies to comprehend the pDNA
traﬃcking mechanism from the cytoplasm into the nucleus
in these cells. Accordingly, this concept will be undoubtedly
extremely useful in future developments of novel vectors
for nonviral gene delivery to human MSC, contributing to
an optimization of the gene delivery processes as well as to
broadening the ﬁeld of MSC applications.
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